Finance Watch: Scorpion Closes $162m Series B, Bringing Recent Total To $270m

$1.67bn In New VC Deals Includes Nearly $1bn In Two Days

Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.

The week before the annual J.P. Morgan Healthcare Conference always includes a bevy of new financings and the week before this year’s 11-14 January meeting kept up with the tradition with $1.67bn in venture capital deals announced through 8 January.

Nearly $1bn – a total of $954.5m in new VC financings – were announced on 7 and 8 January alone by a dozen biopharmaceutical companies, including a $162m series B round for Scorpion Therapeutics, Inc

VC Deals In Depth

Scrip took a deeper look at some of 2021’s first venture capital deals:

Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Hengrui Set For Biggest Biopharma IPO So Far This Year

15 May 2025

• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

13 May 2025

• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

13 May 2025

• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.